Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

Please add ResearchGrants@BrightFocus.org to your institution’s white list to insure that the notification is not blocked by your organization’s SPAM filters.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

BrightFocus Research Grants

Tabbed Applet for Main Research Page
BrightFocus Foundation

BrightFocus has awarded more than $140.3 million to save sight and mind by funding innovative research worldwide, as of July 1, 2014.*

Click on the tabs to learn more about funding opportunities or apply for a grant as it pertains to Alzheimer's, macular degeneration, or glaucoma.

Since 1985, BrightFocus Alzheimer's Disease Research (ADR) has awarded more than $87.7 million to support promising research in fields ranging from molecular biology to epidemiology. ADR is currently supporting 64 outstanding biomedical research projects.

Macular Degeneration Research (MDR) is the newest BrightFocus program. Since 1999, BrightFocus has awarded more than $15.8 million to support basic research into the causes and potential treatments of this disease. MDR is currently supporting 35 biomedical research projects.

Since National Glaucoma Research (NGR) began in 1978, BrightFocus has awarded more than $24.2 million to support basic research into the causes and potential treatments of this disease. NGR is currently supporting 34 biomedical research projects.


 

 

Important Dates

Alzheimer's Disease Research (Research Fellowship Award $100,000 budgeted over 2 years; Standard Award $250,000 budgeted over 3 years)

  • Full proposal due by October 14, 2014
  • Please sign up for email notification of new RFP announcements and application deadlines by using the following link to our website: E-mail notification

Macular Degeneration Research ($160,000 budgeted over 2 years)

  • Letter of Intent due July 31, 2014
  • Full Proposal due November 18, 2014 (by invitation only)

National Glaucoma Research ($100,000 budgeted over 2 years)

  • Full proposal due by November 4, 2014
  • Please sign up for email notification of new RFP announcements and application deadlines by using the following link to our website: E-mail notification
Researcher Spotlight

Stanley Prusiner, M.D.
Stanley Prusiner, M.D., a neurobiologist at the University of California at San Francisco, was awarded the 1997 Nobel Prize in Medicine for his groundbreaking discovery and definition of a new class of disease-causing agents called prions. Dr. Prusiner's early research program was supported by BrightFocus. He now serves as an honorary member of the BrightFocus board of directors. Read more…

Apply for Grant Funding
Find out about current funding opportunities and how to apply for grants online. Find out more...
Research That We Fund
Learn about the promising research we currently support and our previous research over the years.
For Current Awardees
Researchers, find all the necessary reporting forms and follow up information required after receiving a grant. Find out more...
Molecular Neurodegeneration: The Official Journal of BrightFocus
Molecular Neurodegeneration (MN) publishes peer-reviewed, original scientific research on the causes of neurodegenerative diseases, like Alzheimer's or Parkinson's, and on the pre-clinical testing of potential therapies for these devastating diseases. MN now ranks in the top 20 percent of neuroscience journals published worldwide with an impact score of 5.29.


Last Review: 07/10/14